The FDA informed physicians today of a report by GlaxoSmithKline of an increased number of arm, hand, and foot fractures among women taking rosiglitazone (Avandia) for newly diagnosed type 2 diabetes.
The FDA and drug company advised clinicians to carefully consider fracture risk before initiating rosiglitazone therapy.
http://www.medpagetoday.com/Endocrinology/Diabetes/dh/5098
No comments:
Post a Comment